Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018018077) METHODS OF TREATING BREAST CANCER AND REAGENTS THEREFOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/018077 International Application No.: PCT/AU2017/050766
Publication Date: 01.02.2018 International Filing Date: 25.07.2017
IPC:
A61K 48/00 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
GARVAN INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 384 Victoria Street Darlinghurst, New South Wales 2010, AU
PETER MACCALLUM CANCER INSTITUTE [AU/AU]; 305 Grattan Street Melbourne, Victoria 3000, AU
Inventors:
SWARBRICK, Alex; AU
NIKOLIC, Iva; AU
SIMPSON, Kaylene; AU
Agent:
FB RICE; Level 23, 44 Market St Sydney, New South Wales 2000, AU
Priority Data:
201690290825.07.2016AU
Title (EN) METHODS OF TREATING BREAST CANCER AND REAGENTS THEREFOR
(FR) MÉTHODES DE TRAITEMENT DU CANCER DU SEIN ET RÉACTIFS À CET EFFET
Abstract:
(EN) This disclosure relates to RNA interference (RNAi) reagents for treatment of breast cancer, compositions comprising same, and use thereof to treat individuals suffering from breast cancer as a monotherapy or in combination with a chemotherapeutic agent. In particular, the present disclosure relates to microRNAs (miRNAs) which affect viability of breast cancer cells.
(FR) L'invention concerne des réactifs d'interférence ARN (ARNi) pour le traitement du cancer du sein, des compositions les comprenant, et leur utilisation pour traiter des idividus atteints d'un cancer du sein en tant que monothérapie ou en combinaison avec un agent chimiothérapeutique. En particulier, la présente invention concerne des microARN (miARN) qui affectent la viabilité des cellules du cancer du sein.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)